Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study

United States News News

Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study
United States Latest News,United States Headlines
  • 📰 FoxBusiness
  • ⏱ Reading Time:
  • 10 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 53%

COVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.

The first cohort received two doses of the Pfizer-BioNTech vaccine 90-180 days before enrollment and will receive one or two doses of the omicron-based vaccine.

In the second, participants received three doses of the Pfizer-BioNTech vaccine during the same timeframe and will receive one dose of the same vaccine or the omicron-based vaccine.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

FoxBusiness /  🏆 458. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer and BioNTech said Tuesday they've stated clinical trials for an omicron-based COVID-19 vaccine.
Read more »

Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotClinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »

Pfizer and BioNTech begin clinical trial for Omicron-specific vaccinePfizer and BioNTech begin clinical trial for Omicron-specific vaccinePfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday.
Read more »

Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotClinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »

Pfizer starts clinical trial for omicron-specific Covid vaccinePfizer starts clinical trial for omicron-specific Covid vaccineJUST IN: Pfizer and BioNTech announce that they have started a clinical trial testing a modified Covid-19 vaccine to protect against the omicron variant.
Read more »

Pfizer Begins Clinical Trial for Omicron-Specific COVID VaccinePfizer Begins Clinical Trial for Omicron-Specific COVID VaccinePfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant
Read more »



Render Time: 2025-02-24 04:42:31